GlaxoSmithKline (GSK) has received the US Food and Drug Administration (FDA) approval for expanded indication of its ovarian cancer drug Zejula.

The approval enables the use of the drug as maintenance monotherapy for patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Zejula is for women who have had a complete or partial response to first-line platinum-based chemotherapy, irrespective of biomarker status.

The drug is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor.

Previously, the FDA granted approval as monotherapy for women with advanced ovarian cancer beyond those with BRCAm disease. It is meant for the first-line, recurrent maintenance and late-line primary treatment settings.

GSK chief scientific officer and R&D president Dr Hal Barron said: “Women with advanced ovarian cancer have a five-year survival rate of less than 50%.

“This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend the time it takes for their cancer to progress.”